Iosimenol

Drug Profile

Iosimenol

Alternative Names: Iosmin

Latest Information Update: 31 Mar 2010

Price : $50

At a glance

  • Originator Biophysica Inc; Interpharma Praha
  • Developer Interpharma Praha
  • Class Benzamides; Nonionic contrast media; Propanolamines
  • Mechanism of Action Radiography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 26 Aug 2008 Interpharma Praha has been acquired by Otsuka Pharmaceutical
  • 19 Jan 2004 Phase-II/III clinical trials in Undefined indication (diagnosis) in Czech Republic (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top